Fosamprenavir

Protease Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Fosamprenavir is an ofp drug in the Protease Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2003. Its mechanism of action is classified as Cytochrome P450 3A4 Inducers, Cytochrome P450 3A4 Inhibitors and HIV Protease Inhibitors. DrugCentral lists 2 molecular targets, including gag-pol and pol. Recorded indications include Human immunodeficiency virus infection.

• Approval status: ofp (first approved 2003 by the FDA).
• Drug class: Protease Inhibitor.
• Mechanism of action: Cytochrome P450 3A4 Inducers; Cytochrome P450 3A4 Inhibitors; HIV Protease Inhibitors.
• Molecular targets: gag-pol and pol (2 listed in DrugCentral).
• Indications: Human immunodeficiency virus infection.
• ATC code: J05AE07 (Protease inhibitors).
• Molecular formula: C25H36N3O9PS; molecular weight 585.61 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Human immunodeficiency virus infection

Off-label uses (1)

• Prevention of HIV Infection after Exposure

Contraindications (21)

• Breastfeeding (mother)
• Cardiovascular event risk
• Chronic hepatitis C
• Chronic type B viral hepatitis
• Diabetes mellitus
• Disease of liver
• Disorder of coronary artery
• Hemolytic anemia
• Hereditary factor IX deficiency disease
• Hereditary factor VIII deficiency disease
• Hypercholesterolemia
• Hyperglycemia
• Hypertensive disorder
• Hypertriglyceridemia
• Ketoacidosis in diabetes mellitus
• Kidney stone
• Lipodystrophy
• Liver function tests abnormal
• Myocardial infarction
• Obesity
• Smokes tobacco daily

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 3A4 Inducers; Cytochrome P450 3A4 Inhibitors; HIV Protease Inhibitors; P-Glycoprotein Inducers
• Established pharmacologic class: Protease Inhibitor

Molecular targets (2)

Target	Gene	Action	Activity
Gag-Pol polyprotein	gag-pol	unknown	—
Pol polyprotein	pol	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2003-10-20	FDA	—	VIIV HLTHCARE

ATC classification

ATC code	Therapeutic hierarchy
J05AE07	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Protease inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: CYP3A4

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Viral mutation identified	257.3
Virologic failure	250.1
Cystitis noninfective	145.2
Pathogen resistance	123.1
Drug interaction	122.9
Lipodystrophy acquired	112.3
Drug resistance	111.2
Cerebral ischaemia	99.8
Blood HIV RNA increased	99.1
Blood bilirubin increased	79.4
Tumour lysis syndrome	77.9
Foetal exposure during pregnancy	70.1

Chemical structure

• Molecular formula: C₂₅H₃₆N₃O₉PS
• Molecular weight: 585.61 g/mol
• CAS number: 226700-79-4
• InChIKey: MLBVMOWEQCZNCC-OEMFJLHTSA-N
• PubChem CID: 131536

CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Fosamprenavir used for?

DrugCentral lists the following indications for Fosamprenavir: Human immunodeficiency virus infection.

How does Fosamprenavir work?

Fosamprenavir is classified as Cytochrome P450 3A4 Inducers, Cytochrome P450 3A4 Inhibitors and HIV Protease Inhibitors; its molecular targets in DrugCentral include gag-pol and pol (inhibitor).

When was Fosamprenavir first approved?

Fosamprenavir was first approved by the FDA in 2003.

What drug class does Fosamprenavir belong to?

Fosamprenavir is in the Protease Inhibitor class.

What is the chemical formula of Fosamprenavir?

Fosamprenavir has the molecular formula C25H36N3O9PS and a molecular weight of 585.61 g/mol.

Sources

• DrugCentral drug card 1240 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200734 — compound record and bioactivity
• PubChem CID 131536 — chemical identifiers
• DrugBank DB00701 — drug record
• FDA UNII WOU1621EEG — substance identity
• DailyMed: FDA labels for Fosamprenavir — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.